Medical Cannabis Studies

• View All (505)

Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis (2011)

Cannabidiol (CBD) due to its ability to control reactive gliosis in the central nervous system but without the psychotropic effects, can be a new therapeutic alternative in the treatment of inflammatory bowel diseases. View study
Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study (2011)

CBD exhibits antioxidant and anti-inflammatory properties. These data highlight the anti-inflammatory and vascular stabilizing effects of CBD in endotoxic shock and suggest a possible beneficial effect of this natural cannabinoid. View study
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice (2005)

Cannabidiol acts as an agonist of the vanilloid channel 1 in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol also has potential as an antipsychotic. View study
Cannabidiol reverses the mCPP-induced increase in marble-burying behavior (2013)

Cannabidiol (CBD), one of the main components of Cannabis sp., Shows clinical and preclinical anxiolytic properties. This study was based on investigating the interference of (CBD) in the effects of metachlorophenylpiperazine (mCPP), in repetitive burial. View study
Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2 Levels (2009)

In this research we want to characterize the mechanisms by which cannabidi (CBD) regulates Ca 2 homeostasis and mediates neuroprotection in neuronal preparations. The results show that under pathological conditions involving mitochondrial dysfunction and Ca 2 dysregulation, (CDB) may be beneficial to avoid apoptotic signaling through the restoration of Ca 2 homeostasis. View study
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug (2011)

The results of these studies showed that cannabidiol (CBD) reduces anxiety in patients with anxiety disorders. studies can be justified in the future with new medical trials with patients with different anxiety disorders. View study
Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect (2013)

According to the results obtained, it could be concluded that the non-psychoactive CBD was able to produce a significant antitumor activity both in vitro and in vivo, which suggests a possible application of CBD as an antineoplastic agent. View study
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus (2012)

This investigation was based on the evaluation of the hypothesis related to the activation of somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus (DRN) produces the antiemetic / antinausea effects of cannabidiol (CBD), a primary non-psychoactive cannabinoid that is found in cannabis. The results of this investigation show that CBD produced its antiemetic effects against nausea through the indirect activation of somatodendritic 5-HT1A autoreceptors in the DRN. View study
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury (2007)

CBD exhibits antioxidant and anti-inflammatory properties. These data highlight the anti-inflammatory and vascular stabilizing effects of CBD in endotoxic shock and suggest a potential beneficial effect of this natural cannabinoid. View study
Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances (2009)

Using an animal model, this study examines the effects of CBD on the self-administration of heroin and concludes that it can be used effectively in patients with heroin addiction. View study
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (2014)

It has been shown that pure cannabidiol (CBD) has anti-inflammatory and neuroprotective properties. However, studies about the effects of CBD on epilepsy have not been conclusive. For this reason, deeper controlled studies are being planned in target intractable epilepsy populations (in patients with the Dravet and Lennox Gastaut syndromes). View study
Cannabidiol: Promise and Pitfalls (2014)

This review points out a bit of the basic science theory behind the use of CBD, summarizes the published data on its clinical use for epilepsy and exposes the problems related to the use of CBD products at present. View study